About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/22/2021.
This website is for US healthcare professionals

Log In to Bolder Science


Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/22/2021.

Electroconvulsive Therapy (ECT) for Agitation in Alzheimer's Dementia (AD)

Clinicaltrials.gov identifier NCT03926520

Recruitment Status Not yet recruiting

First Posted April 24, 2019

Last update posted July 31, 2019

Study Description

Brief summary:

This study will explore the efficacy of ECT treatments plus usual care (ECT+UC), relative to a placebo simulated ECT plus usual care (S-ECT+UC) in reducing severe agitation in patients with moderate to severe Alzheimer's Disease. The study will also determine the tolerability/safety outcomes of ECT+UC relative to S-ECT+UC.

  • Condition or Disease:Agitation,Psychomotor
    Alzheimer Dementia
  • Intervention/Treatment: Device: Electroconvulsive Therapy (ECT)
    Other: Simulated Electroconvulsive Therapy (S-ECT)
  • Phase: N/A
Detailed Description

This study is a single blind, randomized, Simulated-ECT (S-ECT) controlled trial of electroconvulsive therapy (ECT). The purpose is to determine the efficacy and safety of ECT for severe agitation in moderate to severe stage Alzheimer's Disease (AD), while also examining the durability of the acute treatment effect in an exploratory maintenance naturalistic design. The investigators will study only inpatients with severe agitation and moderate to severe dementia, associated with high care costs and poor quality of life, who typically have already failed prior trials of psychotropic medications. The first aim is to compare the relative efficacy of up to 9 ECT treatments plus usual care (ECT+UC) versus Simulated ECT (S-ECT+UC) in reducing severe agitation in 200 participants with moderate to severe AD. The second aim is to compare the relative tolerability/safety outcomes of ECT+UC versus S-ECT+UC in the same group of participants. The exploratory aim is to understand the stability of agitation reduction (CMAI) and global functioning (ADCS-CGIC) with assessments at 1,3, and 6 months following the acute phase, and then for a fourth visit 12 months after the acute phase. Establishing safety and efficacy of ECT for severe agitation in AD provides an opportunity to decrease long-term care placement, decrease the risk of mortality, decrease caregiver burden, and enhance quality of life for patients and their caregivers.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 200 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Double (Care Provider, Investigator)
  • Primary Purpose: Treatment
  • Official Title: A Randomized Controlled Trial of Electroconvulsive Therapy Plus Usual Care Versus Simulated-ECT Plus Usual Care for the Acute Management of Severe Agitation in Alzheimer's Dementia
  • Estimated Study Start Date: September 2019
  • Estimated Primary Completion Date: March 2023
  • Estimated Study Completion Date: March 2023
Arms and interventions
Arm Intervention/treatment
Experimental: ECT+UC group
Device: Electroconvulsive Therapy (ECT)
Stimulus method of delivery will be RUL electrode placement, and ultra-brief (UB) pulse width (0.25-0.37ms). At the first ECT session, seizure threshold (ST) will be determined by titration with the empirical dose titration method and subsequent treatments will be approximately 6 times the ST. Following other NIMH sponsored multicenter ECT studies (PRIDE, U01 MH055495), stimulus settings will be adjusted as needed during the ECT course based on seizure quality and treatment efficacy. Participants will be administered anesthesia.
Sham Comparator: S-ECT+UC group
Other: Simulated Electroconvulsive Therapy (S-ECT)
The participant is brought to the ECT suite for the length a session would normally take (approximately 2 hours). While in the ECT suite, conducting gel will be placed on the scalp of the S-ECT subjects to parallel the ECT procedures in the ECT active group. A Band-Aid will also be placed on the arm of the S-ECT subjects to parallel the Band-Aid placed at the IV site for the ECT active group. Participants will not be administered anesthesia.
Outcome Measures
  • Primary Outcome Measures: 1. CMAI total score [ Time Frame: The CMAI will be collected through study completion, about 13 months ]
    The CMAI measures the efficacy of ECT+UC in reducing severe agitation in AD subjects than S-ECT. The CMAI is a 29-item scale with each item ranging from 1-7 in frequency with 7 being the highest and therefore worst outcome.
  • Secondary Outcome Measures: 1. Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change Scale (ADCS-CGIC) [ Time Frame: The ADCS-CGIC will be collected through study completion, about 13 months ]
    The ADCS-CGIC gives a discrete score that ranges from 1-7 with 7 being the worst outcome.
  • 2. Neuropsychiatric Inventory (NPI) [ Time Frame: The NPI will be collected for one month ]
    The NPI is composed of several domains in which subscores on frequency and severity will be derived. The higher the frequency and/or severity within each domain, the worse the condition of the patient.
  • 3. Pittsburgh Agitation Scale (PAS) [ Time Frame: The PAS will be collected for one month ]
    The PAS assesses four behavioral domains. Each domain has an intensity score ranging from 0-4 with 4 being the worst outcome.
Eligibility Criteria
  • Ages Eligible for Study: 55 to 89 Years (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Diagnosis of Alzheimer's Dementia according to NIA-AA Criteria for dementia [55]

2. MMSE < 15 3. Cohen-Mansfield Agitation Inventory Short Version (CMAI) score of ≥4 on at least one item, a score of 3 on at least two items, or a score of 2 on at least three items. 4. At least one failed pharmacological intervention to manage behavioral symptoms 5. Medically stable for safe administration of ECT verified by standard physical examination, urinalysis and serum chemistries 6. Comprehension of English language 7. Authorized legal representative able and willing to give informed consent 8. Age 55 - 89 years old (inclusive) Exclusion Criteria: 1. Current diagnosis of co-morbid delirium, measured by the Confusion Assessment Measure (CAM) and by clinical diagnosis 2. Diagnosis of Non-AD Dementia 3. Lifetime or current diagnosis of Schizophrenia, Bipolar Disorder or Schizoaffective Disorder 4. Current episode of Major Depressive Disorder (MDD) 5. Active substance use disorder within past 6 months 6. Treatment with ECT or other neurostimulation therapies (e.g., TMS or vagal nerve stimulation) within the past 3 months

Contacts and Locations

Contact: Emily P Kilpatrick, BA 617-855-3136 ekilpatrick@mclean.harvard.edu

Contact: Aniqa T Rahman, BA 617-855-3257 arahman@mclean.harvard.edu

Sponsors and Collaborators

Brent Forester

Mayo Clinic

Pine Rest Christian Mental Health Services

Emory University

The Zucker Hillside Hospital

Medical University of South Carolina

More Information
  • Responsible Party: Brent Forester
  • ClinicalTrials.gov Identifier: NCT03926520 History of Changes
  • Other Study ID Numbers: 2018P003142
  • First Posted: April 24, 2019 Key Record Dates
  • Last Update Posted: July 31, 2019
  • Last Verified: July 2019
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: Yes
  • Keywords provided by Brent Forester: ECT
  • Additional relevant MeSH terms: Psychomotor Agitation
    Alzheimer Disease